Bendamustine
- Generic Name
- Bendamustine
- Brand Names
- Belrapzo, Bendeka, Treanda, Vivimusta
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21Cl2N3O2
- CAS Number
- 16506-27-7
- Unique Ingredient Identifier
- 9266D9P3PQ
- Background
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...
- Indication
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
- Associated Therapies
- -
A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2011-09-02
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 38
- Registration Number
- NCT00661739
A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2012-01-13
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT00636792
- Locations
- 🇺🇸
MidDakota Clinic - Cancer Treatment and Research Center, Bismarck, North Dakota, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
- Conditions
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2010-07-22
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT00612183
Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-10-22
- Last Posted Date
- 2015-08-06
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 31
- Registration Number
- NCT00547534
- Locations
- 🇺🇸
Cornell Wiell Medical College, New York, New York, United States
🇺🇸Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸University of Rochester Medical Center (James P. Wilmot Cancer Center), Rochester, New York, United States
Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)
- First Posted Date
- 2007-01-25
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- Peter Moosmann
- Target Recruit Count
- 12
- Registration Number
- NCT00426855
A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT00389051
Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL
- Conditions
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2006-10-06
- Lead Sponsor
- University of Magdeburg
- Target Recruit Count
- 30
- Registration Number
- NCT00385125
- Locations
- 🇩🇪
University of Magdeburg, departement of Hematology and Oncology, Magdeburg, Germany
Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 60
- Registration Number
- NCT00274963
- Locations
- 🇩🇪
Schwerpunktpraxis fuer Haematologie und Internistische Onkologie, Berlin, Germany
🇩🇪Internistische Gemeinschaftspraxis - Halle, Halle, Germany
🇩🇪Internistische Praxis - Neuss, Neuss, Germany
Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2019-05-23
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 195
- Registration Number
- NCT00274989
- Locations
- 🇩🇪
HELIOS Klinikum Bad Saarow, Bad Saarow, Germany
🇩🇪Internistische Praxis - Arnstadt, Arnstadt, Germany
🇩🇪Klinikum Augsburg, Augsburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.